Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Growth hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    573 result(s) found for: Growth hormone. Displaying page 3 of 29.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-000929-42 Sponsor Protocol Number: TCH-306 Start Date*: 2021-06-09
    Sponsor Name:Ascendis Pharma Endocrinology Division A/S
    Full Title: foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-controlled (open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin ...
    Medical condition: Adult Growth Hormone Deficiency (AGHD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) FR (Completed) DK (Prematurely Ended) BG (Completed) ES (Ongoing) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000790-36 Sponsor Protocol Number: A6281282 Start Date*: 2008-01-08
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: Prospective, randomized, double blind placebo-controlled trial on the efficacy of growth hormone replacement therapy in adult patients with isolated growth hormone deficiency (PRO ISO-GHD Study)
    Medical condition: Isolated Adult Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056438 Growth hormone deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017354-12 Sponsor Protocol Number: A6281297 Start Date*: 2010-10-11
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
    Full Title: A MULTICENTER, OPEN-LABEL, RANDOMIZED, TWO ARM CROSS-OVER STUDY ASSESSING DYAD (SUBJECT AND CAREGIVER) AND ADULT SUBJECT PERCEPTION OF CONVENIENCE AND PREFERENCE OF THE NEWLY DEVELOPED GENOTROPIN M...
    Medical condition: Subjects with Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    12.1 10056438 Growth hormone deficiency LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) SK (Completed) DE (Completed) GB (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-005442-37 Sponsor Protocol Number: CT200601 Start Date*: 2007-01-08
    Sponsor Name:University Medical Center St Radboud, department of neurology
    Full Title: PITUITARY DAMAGE AFTER TRAUMATIC BRAIN INJURY; Occurrence of growth hormone deficiency at long term follow-up and the beneficial effects of growth hormone substitution on cardiovascular performance...
    Medical condition: isolated growth hormone deficiency after traumatic brain injury
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003410-20 Sponsor Protocol Number: TransCon_hGH_CT-301EXT Start Date*: 2018-04-20
    Sponsor Name:Ascendis Pharma Endocrinology Division A/S
    Full Title: enliGHten: A Multicenter, Phase 3, Long-term, Open-label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children with Growth Hormone Deficiency (GHD) Who Have C...
    Medical condition: Growth hormone deficiency (GHD) in prepubertal children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) GR (Completed) IT (Completed) PL (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-002974-28 Sponsor Protocol Number: NN8640-4468 Start Date*: 2023-07-12
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial comparing the efficacy and safety of once weekly dosing of somapacitan with daily Norditropin® in Chinese children with growth hormone deficiency
    Medical condition: Growth hormone deficiency in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000432-26 Sponsor Protocol Number: versie1,dd01-02-2012 Start Date*: 2012-09-26
    Sponsor Name:Maastricht University Medical Centre
    Full Title: Prospective study on the metabolic and linear growth effects of growh hormone treatment in children with Kabuki Syndrome
    Medical condition: Kabuki Syndrome (KS, OMIM 147920) with a mutation in MLL2 gene.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000874-92 Sponsor Protocol Number: LUM-201-01 Start Date*: 2021-03-22
    Sponsor Name:Lumos Pharma, Inc.
    Full Title: A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficie...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004849-28 Sponsor Protocol Number: FE 999905 CS07 Start Date*: 2009-07-09
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A randomised, open-label, parallel-group, multi-centre trial comparing the efficacy and safety of 12 months treatment with one daily dose of ZOMACTON® to one daily dose of GENOTROPIN® in the treatm...
    Medical condition: Idiopathic growth hormone deficiency.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056438 Growth hormone deficiency LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-000918-38 Sponsor Protocol Number: C0311002 Start Date*: 2019-05-16
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL, CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF WEEKLY GROWTH HORMONE (SOMATROGON) VERSUS DAILY GROWTH HORMONE (GENOTROP...
    Medical condition: Growth Hormone Deficiency in Children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SK (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-001939-21 Sponsor Protocol Number: GX-H9-003 Start Date*: 2015-07-16
    Sponsor Name:Genexine, Inc.
    Full Title: A phase 2, randomized, open-label, active controlled, dose finding study of the long-acting hybrid Fc fused recombinant human growth hormone (GX-H9) in paediatric patients with growth hormone defic...
    Medical condition: Growth Hormone Deficiency (GHD) in pre-pubertal children
    Disease: Version SOC Term Classification Code Term Level
    19.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Prematurely Ended) SK (Completed) GR (Completed) PL (Completed) EE (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000346-36 Sponsor Protocol Number: BPLG-004 Start Date*: Information not available in EudraCT
    Sponsor Name:BioPartners GmbH [...]
    1. BioPartners GmbH
    2. LG Life Science Ltd.
    Full Title: A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of the LB03002 a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Dai...
    Medical condition: pre-pubertal drug naïve growth-deficient children with insufficient endogenous growth hormone secretion
    Disease: Version SOC Term Classification Code Term Level
    10056438 LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) FI (Prematurely Ended) SE (Prematurely Ended) SK (Completed) HU (Completed) CZ (Prematurely Ended) IT (Completed) DE (Completed) LT (Prematurely Ended) EE (Prematurely Ended) LV (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002506-58 Sponsor Protocol Number: EP00-401 Start Date*: 2007-08-14
    Sponsor Name:Sandoz GmbH
    Full Title: Long-term phase IV multicentre study on the safety and efficacy of Omnitrope® (rhGH) in short children born Small for Gestational Age (SGA)
    Medical condition: Growth disturbance (current height standard deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children born small for gestational age (SGA), with a birth weight and/or length be...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10018747 Growth hormone LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001746-40 Sponsor Protocol Number: PRO-ARX201-701 Start Date*: 2008-08-25
    Sponsor Name:Ambrx, Inc., USA
    Full Title: A Phase IIb study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ARX201 Following Repeated Dosing to Young Adult Patients with Childhood Onset Growth Hormone D...
    Medical condition: Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056438 Growth hormone deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-004553-60 Sponsor Protocol Number: CP-4-004 Start Date*: 2012-01-10
    Sponsor Name:OPKO Biologics Ltd.
    Full Title: Safety and dose finding study of different MOD-4023 dose levels compared to daily r-hGH therapy in pre-pubertal growth hormone deficient children
    Medical condition: Pediatric Growth Hormone Deficiency
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) SK (Ongoing) CZ (Prematurely Ended) GR (Completed) PL (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001539-31 Sponsor Protocol Number: FE999905 CS002 Start Date*: 2005-09-16
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-label, Multi-centre, Phase III Study of Local Tolerability of Zomacton 10 mg (Recombinant Somatropin) administered by ZomaJet Vision X
    Medical condition: Zomacton is indicated for the long term treatment of children who have growth failure due to inadequate secretion of growth hormone and for the long-term treatment of growth retardation due to Turn...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-004263-47 Sponsor Protocol Number: EMR200104-011 Start Date*: 2013-03-01
    Sponsor Name:Merck KGaA
    Full Title: Open-label, single-arm, phase IV, multicenter trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD) of adult onset
    Medical condition: Adult Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-017387-16 Sponsor Protocol Number: GH-3826 Start Date*: 2010-08-31
    Sponsor Name:Novo Nordisk Pharmaceutique S.A.S
    Full Title: To assess ease of use, acceptability and preference of Norditropin NordiFlex® in subjects on prescribed growth hormone therapy
    Medical condition: children aged 6 years or more receiving growth hormone therapy for the following approved indications (according to Norditropine SPC) -GHD -Turner Syndrome -small for gestational age -chronic rena...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003874-42 Sponsor Protocol Number: CP-4-006 Start Date*: 2017-09-04
    Sponsor Name:OPKO Biologics Ltd.
    Full Title: A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiency
    Medical condition: Growth hormone deficiency in pre-pubertal children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BG (Completed) FR (Completed) PL (Completed) ES (Ongoing) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004764-31 Sponsor Protocol Number: 02-2006 Start Date*: 2007-01-11
    Sponsor Name:Max Planck Institute of Psychiatry
    Full Title: Effects of corticotropin-releasing hormone on sleep electroencephalogram and sleep associated hormone secretion in young healthy women
    Medical condition: Healthy volunteers. The aim is to test the effects of CRH on sleep electroencephalogram and sleep associated secretion of growth hormone and cortisol
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 09:27:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA